William Tai-Wei Ho - 27 Apr 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)

Role: PRESIDENT AND CEO, Director, 10%+ Owner
Signature: /s/ Jason Minio, Attorney-in-Fact
Issuer symbol: INAB
Transactions as of: 27 Apr 2025
Net transactions value: +$15,107
Form type: 4
Filing time: 07 May 2025, 20:45:13 UTC
Previous filing: 07 Feb 2025
Next filing: 23 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ho William Tai-Wei	PRESIDENT AND CEO, Director, 10%+ Owner	C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK	/s/ Jason Minio, Attorney-in-Fact	07 May 2025	0001830914

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INAB	Series B Warrants (right to buy)	Disposed to Issuer		-81,967	-100%		0	27 Apr 2025	Common Stock	81,967	$1.50	Direct	F1, F2, F3
transaction	INAB	Series B Warrants (right to buy)	Award		+81,967			81,967	27 Apr 2025	Common Stock	81,967	$0.4500	Direct	F1, F2
transaction	INAB	Series A Warrants (right to buy)	Disposed to Issuer		-81,967	-100%		0	01 May 2025	Common Stock	81,967	$0.4500	Direct	F2, F4, F5
transaction	INAB	Pre-Funded Warrant (right to buy)	Award	$15,107	+81,967		$0.1843	81,967	01 May 2025	Common Stock	81,967	$0.000100	Direct	F2, F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.
F2	Fully vested and exercisable.
F3	The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.
F4	Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the "Exchange Agreement"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock, with a per share exercise price of $0.0001 per share.
F5	The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.
F6	The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Pre-Funded Warrants are subject to certain exercise limitations.